FairValueLabs Valuation System Value Investment
CROX

Crocs, Inc. (CROX) Stock Analysis — Fair Value, Risk & Moat Rating

NMS · Consumer Cyclical · Footwear & Accessories

$131.72 Overvalued -0.84 (-0.6%) As of Aug 13, 2026 Not a buy/sell recommendation. See disclaimer.
Overall Verdict Caution
3.63
Altman Z-ScoreSafe Zone
$90.88
Fair ValueOvervalued (-44.9%)
3.7
Moat RatingSolid moat · eroding
TL;DR · Audit Summary

Is Crocs, Inc. a safe investment right now?

As of Aug 13, 2026, our estimated fair value (intrinsic value) for Crocs, Inc. (CROX) stock is $90.88, versus a market price of $131.72 — Overvalued. Predicted EPS $9.18 x 9.9 Fair PE.

Crocs, Inc.'s Altman Z-Score of 3.63 places it in the safe zone. Our fair value estimate is $90.88 (Overvalued). Moat rating: 3.7/5 stars.

Price Chart · CROX
Section 01 · Financial Health

Could Crocs, Inc. go bankrupt? Altman Z-Score analysis

3.63

Z-Score of 3.63 is above 3.0, indicating the company is financially healthy by this metric.

  • Below 1.8 — Distress Zone (high bankruptcy risk)
  • 1.8 to 3.0 — Gray Zone (elevated uncertainty)
  • Above 3.0 — Safe Zone (financially healthy)

What drives CROX's Z-Score?

Altman Z-Score components for CROX
ComponentFormulaValueWeightContribution
A · Working Capital / Total AssetsWC / TA0.04451.20.05
B · Retained Earnings / Total AssetsRE / TA0.83371.41.17
C · EBIT / Total AssetsEBIT / TA0.03863.30.13
D · Market Cap / Total LiabilitiesMCap / TL2.19170.61.32
E · Revenue / Total AssetsRev / TA0.96791.00.97

How has CROX's financial health changed over time?

3.0 Safe1.8 Distress0.01.12.23.44.52022202320242025
CROX Z-Score history
YearZ-ScoreZone
20223.11Safe
20233.62Safe
20243.89Safe
20253.63Safe

Source: Calculated from CROX's latest 10-K filing on SEC EDGAR.

Section 02 · Fair Value Estimate

Crocs, Inc. Fair Value & Intrinsic Value — What Is It Actually Worth?

FVL Fair Value$90.88
vs
Market Price$131.72
Overvalued -44.9% Stock trades 44.9% above our estimated fair value of $90.88.

How we calculated this

FVL Valuation Model
InputValueSource
Predicted EPS (α)$9.18Proprietary blend of reported actuals (2Q actual) + analyst consensus, weighted by α
Last Year EPS$-1.50Annual report (SEC EDGAR)
Analyst Consensus EPS (This Year)$13.9512 analysts consensus
Trailing P/E11.7xCurrent market pricing
Fair P/E (β discount)9.9xTrailing PE adjusted by value discount factor β, hard-capped
Earnings Trend (γ)DecliningDirectional signal: predicted vs trailing EPS

Wall Street Reference: Analyst consensus target price is $138.25 (12 analysts). This is shown for reference only and is not used in our valuation model.

Source: Earnings data from SEC EDGAR filings. Market data via Yahoo Finance.

Section 03 · Competitive Moat

Does Crocs, Inc. have a durable competitive advantage?

★★★½☆
Solid moat · eroding

Moat rating: 3.7/5.

What makes up CROX's moat score?

ROIC Stability

★★★★☆

ROIC variability over the past decade. Score: 4/5.

Gross Margin Trend

★★★★☆

Gross margin trajectory over the past decade. Score: 4/5.

Switching Costs

★★★☆☆

Estimated customer lock-in based on margin level. Score: 3/5.

How stable is CROX's return on invested capital?

0%-5%6%17%27%38%2022202320242025
CROX ROIC history
YearROICTrend
202227.2%
202333.3%Rising
202432.0%Declining
20256.4%Declining

Source: ROIC calculated from SEC EDGAR filings.

Section 04 · Dividend Safety

Is Crocs, Inc.'s dividend safe?

Status Suspended Crocs, Inc. has suspended its dividend. No payout is currently being made to shareholders.
Section 05 · Financial Summary

Crocs, Inc.'s key financial metrics

CROX financial summary
MetricLatest1Y Ago3Y AgoTrend
Revenue $4.0B $4.1B $3.6B Rising
Net Income −$0.1B $1.0B $0.5B Declining
Free Cash Flow $0.7B $0.9B $0.5B Rising
Gross Margin 58.3% 58.8% 52.3% Rising
Section 06 · Lab Signals

Recent events that affect our CROX analysis

EARNINGS

CROX earnings report scheduled

Lab Impact

Upcoming report. Consensus EPS estimate: $3.30. Revenue estimate: $1.00B. Our current Fair Value: $90.88 — a significant beat or miss could shift this estimate.

ANALYST

CROX analyst consensus: 47% bullish (7 of 15 analysts)

Lab Impact

2 Strong Buy, 5 Buy, 7 Hold, 1 Sell, 0 Strong Sell. Consensus target: $138.25 (5.0% upside). Compare with our independent Fair Value: $90.88.

EARNINGS

CROX beat EPS estimates by 4.7%

Lab Impact

Reported EPS: $4.55 vs estimate $4.35. Earnings strength supports our Fair Value of $90.88 (31.0% below current price).

FILING

CROX filed quarterly report (10-Q)

Lab Impact

Quarterly update with interim financials. May signal changes to earnings trajectory and balance sheet health. View on SEC EDGAR →

FILING

CROX filed 8-K (material event)

Lab Impact

8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →

FILING

CROX filed 8-K (material event)

Lab Impact

8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →

EARNINGS

CROX beat EPS estimates by 7.2%

Lab Impact

Reported EPS: $2.99 vs estimate $2.79. Earnings strength supports our Fair Value of $90.88 (31.0% below current price).

FILING

CROX filed quarterly report (10-Q)

Lab Impact

Quarterly update with interim financials. May signal changes to earnings trajectory and balance sheet health. View on SEC EDGAR →

FILING

CROX filed 8-K (material event)

Lab Impact

8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →

EARNINGS

CROX beat EPS estimates by 19.7%

Lab Impact

Reported EPS: $2.29 vs estimate $1.91. Earnings strength supports our Fair Value of $90.88 (31.0% below current price).

FILING

CROX filed annual report (10-K)

Lab Impact

Annual filing with full-year financials. Our Altman Z-Score, Moat, and Fair Value models are derived from this data. View on SEC EDGAR →

FILING

CROX filed 8-K (material event)

Lab Impact

8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →

EARNINGS

CROX beat EPS estimates by 23.7%

Lab Impact

Reported EPS: $2.92 vs estimate $2.36. Earnings strength supports our Fair Value of $90.88 (31.0% below current price).

FILING

CROX filed quarterly report (10-Q)

Lab Impact

Quarterly update with interim financials. May signal changes to earnings trajectory and balance sheet health. View on SEC EDGAR →

FILING

CROX filed 8-K (material event)

Lab Impact

8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →

FILING

CROX filed 8-K (material event)

Lab Impact

8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →

EARNINGS

CROX beat EPS estimates by 5.3%

Lab Impact

Reported EPS: $4.23 vs estimate $4.02. Earnings strength supports our Fair Value of $90.88 (31.0% below current price).

FILING

CROX filed quarterly report (10-Q)

Lab Impact

Quarterly update with interim financials. May signal changes to earnings trajectory and balance sheet health. View on SEC EDGAR →

FILING

CROX filed 8-K (material event)

Lab Impact

8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →

FILING

CROX filed 8-K (material event)

Lab Impact

8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →

FILING

CROX filed 8-K (material event)

Lab Impact

8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →

EARNINGS

CROX beat EPS estimates by 20.6%

Lab Impact

Reported EPS: $3.00 vs estimate $2.49. Earnings strength supports our Fair Value of $90.88 (31.0% below current price).

FILING

CROX filed quarterly report (10-Q)

Lab Impact

Quarterly update with interim financials. May signal changes to earnings trajectory and balance sheet health. View on SEC EDGAR →

FILING

CROX filed 8-K (material event)

Lab Impact

8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →

FILING

CROX filed 8-K (material event)

Lab Impact

8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →

EARNINGS

CROX beat EPS estimates by 11.3%

Lab Impact

Reported EPS: $2.52 vs estimate $2.26. Earnings strength supports our Fair Value of $90.88 (31.0% below current price).

FILING

CROX filed annual report (10-K)

Lab Impact

Annual filing with full-year financials. Our Altman Z-Score, Moat, and Fair Value models are derived from this data. View on SEC EDGAR →

FILING

CROX filed 8-K (material event)

Lab Impact

8-K filings disclose material events — acquisitions, leadership changes, or guidance revisions that may affect valuation. View on SEC EDGAR →

Section 07 · FAQ

Common questions about Crocs, Inc.

What is Crocs, Inc. stock price today?

Crocs, Inc. (CROX) stock price is $131.72 as of the latest market close, traded on the NASDAQ exchange.

What does Crocs, Inc. do?

Crocs, Inc. together with its subsidiaries, designs, develops, manufactures, markets, distributes, and sells casual lifestyle footwear and accessories for men, women, and kids under the Crocs and HEYDUDE Brands in the United States and internationally. It offers various footwear products, including clogs, sandals, loafers, classics, fuzz, platforms, boots, sandals, slides, slippers, sneakers, flip flops, and flats, as well as totes, backpacks, belt bags, socks, bag charms, cases, attachments, cartoon characters products, and touchland and other accessories.

What is Crocs, Inc. market cap?

Crocs, Inc. has a market capitalization of $6.32B, classifying it as a mid-cap stock in the Consumer Cyclical sector.

What sector and industry is CROX in?

Crocs, Inc. operates in the Consumer Cyclical sector, specifically within the Footwear & Accessories industry. It trades on the NASDAQ under the ticker symbol CROX.

Is CROX stock overvalued or undervalued?

Based on our valuation model, Crocs, Inc. trades 44.9% above our fair value estimate — potentially overvalued.

  • FairValueLabs Fair Value: $90.88
  • Current Price: $131.72
  • Valuation Zone: Overvalued
What is CROX stock forecast and analyst target price?

Based on 12 Wall Street analysts, the consensus price target for Crocs, Inc. is $138.25, implying upside of 5.0% from the current price.

  • Analyst High Target: $163.00
  • Analyst Low Target: $95.00

Note: Analyst targets are shown for reference and are not used in our valuation model.

Is Crocs, Inc. revenue and earnings growing?

Here are the analyst consensus growth estimates for Crocs, Inc.:

  • Revenue growth (current year est.): 1.5%
  • EPS growth (current year est.): 11.5%
  • Revenue growth (next year est.): 2.5%
  • EPS growth (next year est.): 7.2%
What are Crocs, Inc.'s key financial metrics?
MetricLatestTrend
Revenue$4.0BRising
Net Income−$0.1BDeclining
Free Cash Flow$0.7BRising
Gross Margin58.3%Rising
What is CROX's P/E ratio?

The price-to-earnings ratio measures how much investors pay per dollar of earnings:

  • Trailing P/E (last 12 months): 11.7x
  • Forward P/E (next 12 months est.): 8.8x
  • FairValueLabs Fair P/E: 9.9x
How volatile is CROX stock?

Crocs, Inc. has a beta of 1.53, meaning it is significantly more volatile than the broader market. A beta above 1.0 indicates higher price swings relative to the S&P 500, while below 1.0 suggests more stability.

How much cash and debt does Crocs, Inc. have?

Crocs, Inc.'s balance sheet shows:

  • Total Cash: $170.3M
  • Total Debt: $1.69B
  • Net Cash Position: $-1.52B

A positive net cash position means the company holds more cash than debt, reducing financial risk.

What is Crocs, Inc.'s free cash flow?

Crocs, Inc. generated $533.9M in trailing twelve-month free cash flow (from $762.6M in operating cash flow). Free cash flow represents the cash available for dividends, buybacks, and debt reduction after all capital expenditures.

Does Crocs, Inc. pay a dividend?

Crocs, Inc. does not currently pay a regular dividend to shareholders. The company may be reinvesting all profits back into growth, or it may have suspended its dividend.

Is Crocs, Inc. at risk of going bankrupt?

Crocs, Inc.'s Altman Z-Score is 3.63, placing it in the safe zone (above 3.0) — bankruptcy risk is low. The Z-Score uses five balance sheet ratios to predict bankruptcy probability within two years.

Does Crocs, Inc. have a durable competitive advantage?

Crocs, Inc. scores 3.7/5 stars (Solid moat · eroding) in our moat analysis:

  • ROIC Stability: 4/5
  • Gross Margin Trend: 4/5
  • Switching Costs: 3/5

A score above 3.5 suggests meaningful pricing power and a defensible market position.

What is CROX's return on equity (ROE)?

Crocs, Inc.'s return on equity is 42.3%. ROE measures how efficiently a company generates profits from shareholder equity. An ROE above 15% is generally considered strong, while below 10% may signal inefficiency.

How do I buy CROX stock?

CROX shares can be purchased through any brokerage account that provides access to the NASDAQ. Common steps:

  1. Open an account with a broker (e.g., Fidelity, Schwab, Interactive Brokers)
  2. Search for ticker symbol CROX
  3. Place a market or limit order for your desired number of shares

This is not investment advice. Always do your own research before buying any stock.

Is CROX a value stock or speculative?

FairValueLabs classifies Crocs, Inc. as Value Investment. It exhibits consistent profitability, reasonable valuation, and financial stability — characteristics of a traditional value investment.

Who is the CEO of Crocs, Inc.?

The current CEO of Crocs, Inc. is Mr. Andrew Rees.

What is CROX's earnings per share (EPS)?

Earnings per share measures the company's profit allocated to each outstanding share:

  • Trailing EPS (last 12 months): $11.27
  • Forward EPS (next 12 months est.): $14.95
  • Analyst consensus EPS (this year): $13.95
  • Analyst consensus EPS (next year): $14.95

FairValueLabs Disclaimer

All valuations, scores, ratings, and classifications on this page are produced by the FairValueLabs internal valuation system. They do not represent actual market value, guaranteed outcomes, or professional investment advice. These are analytical estimates for educational and research purposes only.

This is not financial advice. All data is sourced from SEC EDGAR public filings. Always consult a qualified financial advisor before making investment decisions.

Last updated: Aug 13, 2026. Data sources: SEC EDGAR (financial statements), Yahoo Finance (market data, analyst consensus). Data may not reflect the most recent quarter.

CROX analysis methodology: How we calculate fair value, Z-Scores, and moat ratings